Novel concepts of treating vascular inflammation underlying neonatal lung diseases
Journal of Applied Physiology · 2023
DOI: 10.1152/japplphysiol.00549.2022 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Applied Physiology, 2023. Verfasst von Arvind Sehgal und 3 weiteren Autor:innen. Beteiligte Einrichtung: Monash Newborn, Monash Children's Hospital, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Glucocorticoids, Bronchopulmonary Dysplasia. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 103 Literaturangaben.
Abstract (Originalsprache)
Bronchopulmonary dysplasia (BPD) is the most common sequela of prematurity. Although multifactorial in etiology, there is increasing evidence that fetal growth restriction (FGR) and antenatal exposure of the fetus to inflammation play important roles in the postnatal pathophysiology of BPD. Recent studies have focused on disrupted angiogenesis and its influence on alveolarization. Although there are multiple mechanistic links, inflammation is known to be a key driver of this disruption, affecting pulmonary arterial circulation. Although postnatal corticosteroids are commonly used in extremely premature infants to treat inflammation, aimed at obviating the need for intubation and mechanical ventilation or to facilitate extubation, the use of dexamethasone has not reduced the incidence of BPD. Here, we summarize current knowledge on alternative anti-inflammatory treatment options, which have shown promising outcomes either preclinically or clinically. These include supplementation with vitamins C and E (antioxidants), ω-3 polyunsaturated fatty acids, pentoxifylline, anti-inflammatory cytokines of the IL (interleukin)-1 family, namely IL-1 receptor antagonist and IL-37, and the beneficial properties of breast milk. Evaluating these alternative treatments, either individually or as combination therapies in randomized controlled trials stands to immensely benefit the clinical outlook, particularly regarding BPD, for extremely premature infants.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Monash Newborn, Monash Children's Hospital, Melbourne, Victoria, Australia.
- Department of Paediatrics, Monash University, Melbourne, Victoria, Australia.
- Ritchie Centre, Hudson Institute of Medical Research, Melbourne, Victoria, Australia.
ORCID-Profile: Arvind Sehgal, Steven P Garrick
Zitieren
APA
Sehgal, A., Garrick, S. P., Nold, M. F., & Nold-Petry, C. A. (2023). Novel concepts of treating vascular inflammation underlying neonatal lung diseases. Journal of Applied Physiology. https://doi.org/10.1152/japplphysiol.00549.2022
Vancouver
Sehgal A, Garrick SP, Nold MF, Nold-Petry CA. Novel concepts of treating vascular inflammation underlying neonatal lung diseases. Journal of Applied Physiology. 2023. doi:10.1152/japplphysiol.00549.2022
BibTeX
@article{Sehgal2023,
author = {Sehgal, Arvind and Garrick, Steven P and Nold, Marcel F and Nold-Petry, Claudia A},
title = {Novel concepts of treating vascular inflammation underlying neonatal lung diseases},
journal = {Journal of Applied Physiology},
year = {2023},
doi = {10.1152/japplphysiol.00549.2022}
}
EUVIMED